U.S. market Open. Closes in 3 hours 51 minutes

OABI | OmniAb, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.89 - 4.01
52 Week Range 3.56 - 6.72
Beta 2.01
Implied Volatility 289.72%
IV Rank 40.32%
Day's Volume 97,390
Average Volume 413,785
Shares Outstanding 121,012,580
Market Cap 481,630,068
Sector Healthcare
Industry Biotechnology
IPO Date 2021-09-30
Valuation
Profitability
Growth
Health
P/E Ratio -6.42
Forward P/E Ratio N/A
EPS -0.62
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 106
Country USA
Website OABI
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
*Chart delayed
Analyzing fundamentals for OABI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see OABI Fundamentals page.

Watching at OABI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on OABI Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙